Literature DB >> 15985111

Plasma cytokine levels in migraineurs and controls.

Francesco Perini1, Giovanni D'Andrea, Elisabetta Galloni, Francesco Pignatelli, Giuseppe Billo, Sabrina Alba, Gennaro Bussone, Vito Toso.   

Abstract

BACKGROUND: The vasoactive peptide, calcitonin gene-related peptide (CGRP), is released from primary afferent neurons in the trigemino-vascular circulation during migraine headache. CGRP at physiological concentrations and possibly via stimulation of its selective receptors on T-cells, triggers the secretion of cytokines. Cytokines play an important role in several physiological and pathological settings such as immunology, inflammation, and pain.
OBJECTIVE: To investigate plasma levels of pro- and anti-inflammatory cytokines in migraineurs and healthy controls.
METHODS: We studied 25 migraine patients, during and outside attacks, and 18 healthy control subjects measuring plasma levels of IL-6, IL-10, tumor necrosis factor alpha (TNFalpha), IL-4, IL-1 beta, and IL-2 using ELISA.
RESULTS: Circulating levels of IL-10, TNFalpha, and IL-1 beta during attacks were significantly higher in comparison to their levels outside attacks (P=.0003, P=.03, and P=.05, respectively). IL-10 and TNF serum levels were higher in patients studied soon after headache onset and lower over time (P=.004 and P=.05).
CONCLUSION: Our results suggest that TNFalpha, IL-1 beta, and IL-10 may be involved in the pathogenesis of migraine attacks.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15985111     DOI: 10.1111/j.1526-4610.2005.05135.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  79 in total

1.  Local action of the proinflammatory cytokines IL-1β and IL-6 on intracranial meningeal nociceptors.

Authors:  Xichun Zhang; Rami Burstein; Dan Levy
Journal:  Cephalalgia       Date:  2011-12-05       Impact factor: 6.292

Review 2.  Tumour necrosis factor gene polymorphisms and migraine: a systematic review and meta-analysis.

Authors:  Markus Schürks; Pamela M Rist; Robert Yl Zee; Daniel I Chasman; Tobias Kurth
Journal:  Cephalalgia       Date:  2011-10       Impact factor: 6.292

3.  Increased risk of multiple sclerosis among women with migraine in the Nurses' Health Study II.

Authors:  Ilya Kister; Kassandra L Munger; Joseph Herbert; Alberto Ascherio
Journal:  Mult Scler       Date:  2011-08-03       Impact factor: 6.312

Review 4.  Chronic pain disorders and headache chronification.

Authors:  Thomas McFate; Ann I Scher
Journal:  Curr Pain Headache Rep       Date:  2009-08

Review 5.  Migraine with aura: conventional and non-conventional treatments.

Authors:  Giovanni D'Andrea; Davide Colavito; Maurizio Dalle Carbonare; Alberta Leon
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

6.  Non-alcoholic fatty liver disease in patients with migraine.

Authors:  Asuman Celikbilek; Mehmet Celikbilek; Aylin Okur; Serkan Dogan; Elif Borekci; Mustafa Kozan; Sebnem Gursoy
Journal:  Neurol Sci       Date:  2014-04-23       Impact factor: 3.307

7.  Vitamin D in migraine headache: a comprehensive review on literature.

Authors:  Zeinab Ghorbani; Mansoureh Togha; Pegah Rafiee; Zeynab Sadat Ahmadi; Reyhaneh Rasekh Magham; Samane Haghighi; Soodeh Razeghi Jahromi; Maryam Mahmoudi
Journal:  Neurol Sci       Date:  2019-08-03       Impact factor: 3.307

8.  Gut Microbiota Dysbiosis Enhances Migraine-Like Pain Via TNFα Upregulation.

Authors:  Yuanyuan Tang; Sufang Liu; Hui Shu; Lora Yanagisawa; Feng Tao
Journal:  Mol Neurobiol       Date:  2019-08-04       Impact factor: 5.590

9.  Polymorphism in apolipoprotein E among migraineurs and tension-type headache subjects.

Authors:  Ravi Gupta; Vivek Kumar; Kalpana Luthra; Basudeb Banerjee; Manjeet Singh Bhatia
Journal:  J Headache Pain       Date:  2009-01-31       Impact factor: 7.277

10.  Comparison of oxidative stress among migraineurs, tension-type headache subjects, and a control group.

Authors:  Ravi Gupta; Rahul Pathak; Manjeet Singh Bhatia; Basu Deb Banerjee
Journal:  Ann Indian Acad Neurol       Date:  2009-07       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.